Personalized Melanoma Vaccine Cuts Recurrence Risk in Phase 3
A personalized neoantigen vaccine met its primary endpoint, reducing melanoma recurrence risk after resection in a phase 3 trial — a first for individually tailored cancer immunotherapy.
Topic
Personalized Vaccine
Topic
Personalized Vaccine
Personalized Melanoma Vaccine Cuts Recurrence Risk at Five Years
A personalized melanoma vaccine reduced the risk of cancer recurrence over five years, NBC News reports — one of the longest dura…